Understanding and Caring for Patients with Nonmelanoma Skin Cancers — Nursing Video Interview

Faculty

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of nonmelanoma skin cancers.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with nonmelanoma skin cancers. 

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of novel therapies for nonmelanoma skin cancers and the management of associated treatment-related toxicities in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Recall long-term outcomes with traditional treatment approaches for localized or locally advanced cutaneous squamous cell carcinoma (cSCC), and recognize clinical and histologic features that increase the risk of recurrence after primary therapy.
• Evaluate available research findings with immunotherapeutic agents as a component of neoadjuvant therapy for patients with resectable cSCC in order to identify appropriate candidates for this strategy.
• Appreciate published Phase III data supporting adjuvant anti-PD-1 antibody therapy after surgery and radiation therapy for patients with high-risk cSCC, and assess the optimal use of and practical considerations with this novel approach.
• Use available clinical trial evidence to safely and effectively integrate immunotherapeutic approaches into the care of patients with advanced or metastatic cSCC.
• Formulate a long-term plan for the management of locally advanced or metastatic basal cell carcinoma (BCC), incorporating targeted and immunotherapeutic strategies.
• Implement a plan to manage the side effects associated with approved therapies used in the care of patients with cSCC and BCC, in order to support quality of life and continuation of treatment.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1 contact hour is provided by RTP during the period of May 6, 2026, to May 6, 2027.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONU2026/NonmelanomaSkin/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONU2026/NonmelanomaSkin/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Nikhil I Khushalani, MD
Senior Member and Vice Chair
Department of Cutaneous Oncology
Moffitt Cancer Center
Tampa, Florida

Dr Khushalani is on advisory committees and has consulting agreements with Bristol Myers Squibb, Castle Biosciences Incorporated, Delcath Systems Inc, Immunocore, Instil Bio, IO Biotech, Iovance Biotherapeutics, Merck, Mural Oncology Inc, MyCareGorithm, Nektar Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune, Sun Pharmaceutical Industries Limited; has contracted research (all to institution) with BioNTech SE, Bristol Myers Squibb, Celgene Corporation, GSK, HUYABIO International, IDEAYA Biosciences, Merck, Modulation Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune; is on data and safety monitoring boards/committees for AstraZeneca Pharmaceuticals LP, Incyte Corporation; holds stock OPTIONS — private companies in Asensus Surgical; and holds stock options/stock — public companies in Bellicum Pharmaceuticals Inc.  All of these relevant financial relationships have been mitigated.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Regeneron Pharmaceuticals Inc.

Release date: May 7, 2026
Expiration date: May 7, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Khushalani

Bossi P et al. Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: The I-TACKLE trial. Eur J Cancer 2025;220:115379. Abstract

Breukers SE et al. Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: A randomized phase 2 trial. Nat Med 2025;31(12):4055-64. Abstract

Carter JB et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: An 11-year cohort study. JAMA Dermatol 2013;149(1):35-41. Abstract

Gibson FT et al. Association of cutaneous immune-related adverse events with improved overall survival among patients with cutaneous squamous cell carcinoma treated with palliative programmed death receptor-1 inhibition. J Am Acad Dermatol 2025;92(6):1399-402. Abstract

Gross ND et al. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: Follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol 2023;24(11):1196-205. Abstract

Gross ND et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022;387(17):1557-68. Abstract

Hughes BGM et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021;32(10):1276-85. Abstract

Huis in’t Veld EA et al. Oncological outcome after lymph node dissection for cutaneous squamous cell carcinoma. Ann Surg Oncol 2023;30(8):5017-26. Abstract

Karia PS et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014;32(4):327-34. Abstract

Koyfman SA et al. Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT). ASCO 2025;Abstract 6000.

Marin-Acevedo JA et al. Cetuximab for immunotherapy-refractory/ineligible cutaneous squamous cell carcinoma. Cancers (Basel) 2023;15(12):3180. Abstract

Migden MR et al. Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC). ASCO 2025;Abstract TPS9612.

Porceddu SV et al. Prognostic subgroups for disease-free survival with cutaneous squamous cell carcinoma of the head and neck: A secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2025;151(10):938-45. Abstract

Porceddu SV et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: The randomized phase III TROG 05.01 trial. J Clin Oncol 2018;36(13):1275-83. Abstract

Ran NA et al. Risk factor number and recurrence, metastasis, and disease-related death in cutaneous squamous cell carcinoma. JAMA Dermatol 2025;161(6):597-604. Abstract

Rischin D et al. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med 2025;393(8):774-85. Abstract

Rischin D et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021;9(8):e002757. Abstract

Ruiz ES et al. Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a pivotal open-label study with a median follow-up of ≥2 years. J Am Acad Dermatol 2026;94(1):48-56. Abstract

Dr Wuthrick

Gross ND et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022;387(17):1557-68. Abstract

Ladwa R et al. Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: The De-Squamate study. J Clin Oncol 2025;43(26):2888-96. Abstract

Veness MJ et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice. Laryngoscope 2005;115(5):870-5. Abstract

Wang JT et al. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head Neck 2012;34(11):1524-8. Abstract

Dr Park

Barker CA et al. Phase II, single-arm trial of induction and concurrent vismodegib with curative-intent radiation therapy for locally advanced, unresectable basal cell carcinoma. J Clin Oncol 2024;42(19):2327-35. Abstract

Bertrand N et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine 2021;35:100844. Abstract

Chang ALS et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol 2019;80(2):564-6. Abstract

Dummer R et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol 2020;182(6):1369-78. Abstract

Jones GM et al. Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial. AACR 2024;Abstract 7518.

Lewis KD et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol 2024;35(2):221-8. Abstract

Sekulic A et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017;17(1):332. Abstract

Stratigos AJ et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):848-57. Abstract

Warrier G et al. Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) w/ treatment-naïve or -refractory advanced basal cell carcinoma (aBCC). ESMO 2025;Abstract 1667P.

Dr Patel

Cañueto J et al. Postoperative radiotherapy provides better local control and long-term outcome in selective cases of cutaneous squamous cell carcinoma with perineural invasion. J Eur Acad Dermatol Venereol 2020;34(5):1080-91. Abstract

Conde-Ferreirós A et al. Definition of prognostic subgroups in the T3 stage of the eighth edition of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Tentative T3 stage subclassification. J Am Acad Dermatol 2021;85(5):1168-77. Abstract

Dong J et al. Risk factors for recurrent and metastatic cutaneous squamous cell carcinoma in immunocompromised patients. J Am Acad Dermatol 2020;83(5):1473-5. Abstract

Dusendang JR et al. Cohort and nested case-control study of cutaneous squamous cell carcinoma in solid organ transplant recipients, by medication. J Am Acad Dermatol 2022;86(3):598-606. Abstract

Kim Y et al. Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. J Am Acad Dermatol 2022;86(6):1246-57. Abstract

Lopez A et al. Immunosuppressed patients are at increased risk of local recurrence, metastasis, and disease specific death from cutaneous squamous cell carcinoma. Arch Dermatol Res 2023;315(5):1429-33. Abstract

Mahajan S et al. Restaging [¹⁸F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance. J Am Acad Dermatol 2020;82(4):878-86. Abstract

Morgan FC et al. Brigham and Women’s Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. J Am Acad Dermatol 2021;85(3):582-7. Abstract

Morgan FC et al. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. J Am Acad Dermatol 2020;83(3):832-8. Abstract

Ruiz ES et al. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. J Am Acad Dermatol 2022;87(1):87-94. Abstract

Ruiz ES et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs the Brigham and Women’s Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019;155(7):819-25. Abstract

Ruiz ES et al. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol 2017;76(2):217-25. Abstract

Tschetter AJ et al. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study.J Am Acad Dermatol 2020;82(1):139-48. Abstract